A Phase I Study of BEZ235, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2013
At a glance
- Drugs Dactolisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2013 Planned end date changed from 1 Jul 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History